L’Hôpital Privé du Confluent in Nantes, France has ordered PrepLog® systems. The system is to be used for final control of cytotoxic drugs at the hospital pharmacy and will be integrated with the hospital’s prescribing system. Nantes has been using DrugLog® clinically since 2017. The agreement is entered into with Pharmacolog France SARL.
L’Hôpital Privé du Confluent (PYR) in Nantes has for a number of years used DrugLog® for final control of cytotoxic preparations made at the hospital pharmacy. PYR has now signed an agreement with Pharmacolog France SARL to install the new PrepLog system that enables integration with their prescription software Chimio, from the company Computer Engineering. The integrated solution means improved workflow and automated reporting functions. The order amount for the French subsidiary is approximately SEK 850 000 over 4 years.
CEO Mats Högberg comments: “It is extremely gratifying that Nantes has decided to move forward with Pharmacolog and is investing in upgrading to PrepLog®. Nantes has used an early version of DrugLog® clinically for several years with good results but will, as they switch to PrepLog®, further streamline their quality control. PrepLog® allows a fully integrated workflow and complete traceability of test results that was not previously possible.”
This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 16, 2020 at 09:30.
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.
Release